Find policies, billing codes, payers, states, and providers
Cervical Cancer Screening
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage criteria and limits for cervical cancer screening (Pap cytology, high-risk HPV testing, and co-testing) for individuals with a cervix, including special populations such as immunocompromised individuals and those with prior abnormal results.
No material clinical or coverage changes in this revision.
Coverage Criteria — Cervical Cancer Screening
Immunocompromised or immunosuppressed individuals
Covered when ANY of the following are met:
Individuals 21 to 29 years of age
Covered when ALL of the following are met:
HPV primary testing not preferred for this age group per policy guidance.
Individuals 30 to 65 years of age
Covered when ANY of the following are met:
Co-testing frequency listed as 5 years in policy text.
Pooled hr-HPV positive individuals
Genotyping to stratify risk and guide further management.
Individuals <=65 years with prior abnormal/ high-risk features
Covered when ANY of the following are met:
Applies up to age 65 per policy language.
Not indicated / does not meet criteria
Policy statement III.7.
Policy statement III.8.
Policy statement III.9.
Policy statement III.10.
Routine screening of average-risk individuals
Covered when meeting guideline age and interval recommendations:
USPSTF Grade A recommendation for persons 21–65.
Not recommended (routine) populations
Not covered routinely when:
USPSTF recommends against routine screening in these groups (Grade D).
Immunocompromised / special population screening
Covered with intensified surveillance for immunocompromised individuals:
Applies to transplant recipients, HSCT with GVHD, IBD or rheumatologic disease on immunosuppressants per ASCCP guidance.
Management after positive HPV or abnormal cytology
Risk-based management and reflex testing requirements:
HPV 16/18 positivity carries highest CIN3+ risk and warrants expedited evaluation.
Expedited treatment requires cytology to have been performed.
ASCCP and ACOG endorse extended long-term surveillance.
Self-sampling (vaginal HPV) for screening
Acceptable alternatives and follow-up requirements:
Recommendations based on Enduring Consensus 2025 update; genotype-specific follow-up pathways described.
Covered screening, triage, and post-treatment surveillance
General coverage approach based on referenced guidelines:
References include CDC, ASCO, ACOG.
ACOG and CDC recommend reflex testing; ASCO recommends reflex genotyping or cytology.
ACOG states elevated risk persists for ≥25 years.
HIV-specific screening and follow-up
Persons with HIV — CDC/HHS specific recommendations:
HHS guidance.
HHS guidance includes genotype-directed colposcopy.
Resource-stratified screening and management
ASCO resource-stratified recommendations (selected):
ASCO 2022 recommendations.
ASCO 2022.
ASCO resource-stratified guidance.
Routine cervical cancer screening DOES NOT MEET CRITERIA for individuals over 65 years who are not immunocompromised, immunosuppressed, or otherwise at high risk (for example, those without a history of abnormal cytology or prior positive hr‑HPV). This policy statement reflects the limitation in Section III that routine screening in this population is not covered absent qualifying risk factors.
Screening is not beneficial for people who no longer have a cervix as a result of a hysterectomy performed for benign disease. The National Cancer Institute and this policy state that cervical cancer screening in women without a cervix for benign indications does not meet criteria.
Testing for low‑risk HPV types (the non‑oncogenic types associated with genital warts) is not recommended. The American Academy of Family Physicians advises: 'Don't perform low‑risk human papillomavirus (HPV) testing' because identification of low‑risk types does not alter clinical management or predict progression to cervical precancer or cancer.
No additional explicit exclusions are listed in this section of the policy beyond the specified age, post‑hysterectomy, and technology exclusions noted elsewhere. Procedure code guidance (e.g., G0476) appears in the coding section but does not by itself create new exclusions.
For clinical situations not specifically addressed by the policy's covered criteria, cervical cancer screening does not meet criteria unless coverage is supported by another policy section or an applicable guideline. The policy notes that technologies not discussed in the document do not meet criteria due to lack of sufficient published evidence.
Routine screening outside the guideline age ranges—specifically, screening individuals younger than 21 years or older than 65 years with adequate prior negative screening—is considered not beneficial per USPSTF and the National Cancer Institute and therefore does not meet criteria for routine screening.
Testing specifically for low‑risk HPV types (those that cause genital warts) is not indicated for cervical cancer screening because these types are not associated with progression to cervical precancer or cancer and identification would not change management.
There are no explicit 'not medically necessary' statements listed in this section beyond the age, post‑hysterectomy, and technology limitations already described. The policy's not‑medically‑necessary listings reiterate that technologies not discussed lack sufficient evidence to meet criteria.
Procedure and Billing Codes
| 88141 | Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician. |
| 88142 | Cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision. |
| 88147 | Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision. |
| 88148 | Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision. |
| 88150 | Cytopathology, slides, cervical or vaginal; manual screening under physician supervision. |
| 88152 | Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision. |
| 88153 | Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision. |
| 88164 | Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision. |
| 88165 | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision. |
| 88166 | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision. |
| G0123 | Screening cytopathology, preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision. |
| G0124 | Screening cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician. |
| G0141 | Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician. |
| 88152 | Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision. |
| 88153 | Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision. |
| 88164 | Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision. |
| 88165 | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision. |
| 88166 | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision. |
| 88167 | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening using cell selection and review under physician supervision. |
| 88174 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision. |
| 88175 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision. |
| G0123 | Preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision. |
| G0124 | Screening cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician. |
| G0141 | Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician. |
| G0476 | Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (hpv), high-risk types for cervical cancer screening, must be performed in addition to pap test. |
| P3000 | Screening Papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision. |
| P3001 | Screening Papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician. |
| Q0091 | Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory. |
Provider Actions, Documentation, and Billing Guidance
Authorization and medical necessity
Coverage and reimbursement are conditioned on meeting applicable authorization and medical necessity requirements and the member's state of residence; services must meet those requirements to be reimbursed.
Reflex testing and colposcopy workflow
All positive primary HPV screening tests require reflex triage testing (e.g., reflex cytology or genotyping) performed from the same laboratory specimen; if same-specimen reflex testing is not feasible and HPV-16/18 is positive, proceed directly to colposcopy and collect an additional triage specimen at that visit.
- Perform reflex cytology or genotyping from the same specimen for every positive primary HPV test.
- If same-specimen reflex testing is not feasible and HPV 16 or 18 is positive, refer to colposcopy and obtain additional triage testing at colposcopy.
Procedure coding to submit
Submit claims with the applicable HPV nucleic acid and cytopathology procedure codes listed in the policy for screening, reflex, cotesting, and cytology services.
Prior authorization for listed codes
This policy does not list explicit prior authorization requirements for the procedure codes shown in the policy section.
Follow screening criteria and document rationale
Providers are expected to follow the policy's screening criteria and reflex testing requirements when managing HPV-positive or abnormal cytology results; document rationale and test results to support medical necessity decisions.
Risk-based triage (non‑pharmacologic) workflow
When managing positive HPV or abnormal cytology, follow the policy's risk-based pathways (reflex cytology/genotyping and colposcopy per genotype and cytology) rather than a stepwise pharmacologic step-therapy approach.
Provider documentation obligation
Providers must submit accurate documentation of services performed and code claims according to industry-standard coding guidelines; failure to follow coding/billing guidelines may result in denial or recoupment.
- Code claims per CPT, HCPCS, ICD-10 and other applicable coding guidance.
- Maintain documentation supporting services performed and medical necessity.
Required documentation for positive HPV tests and cessation
Ensure reflex triage testing is performed from the same specimen for positive primary HPV tests and that genotype (HPV‑16/18) results are documented when obtained; document prior screening history when making cessation decisions.
- Document reflex cytology or genotyping performed from the same specimen for every positive primary HPV screen.
- Record HPV genotype (notably HPV‑16/18) results when performed.
- Document prior screening history when deciding to stop screening.
Reflex testing documentation
Document that reflex triage testing (e.g., reflex cytology or genotyping) was performed from the same laboratory specimen for all positive primary HPV screening tests; if reflex testing was not feasible, document that and the actions taken (eg, direct colposcopy).
- Support claims by showing same-specimen reflex testing occurred or why it was not feasible.
- If reflex testing was not feasible and colposcopy was performed, document collection of an additional triage specimen at colposcopy.
Pap test documentation when billing G0476
When billing G0476, document that a Pap test was performed because G0476 specifies HPV nucleic acid testing for cervical cancer screening must be performed in addition to a Pap test.
- Include documentation of Pap test collection and interpretation when submitting claims with G0476.
Coding and documentation compliance risk
Claims may be denied or recouped if coding/billing guidelines or reimbursement policies are not followed or if appropriate documentation is not provided to support the service.
Age‑based screening denial risk
Screening performed outside recommended age ranges — e.g., routine screening for individuals younger than 21 or older than 65 with adequate prior screening — is not recommended by USPSTF and may be denied if not justified by documented risk factors.
- Provide documentation of high-risk conditions if screening outside recommended age ranges is performed.
Follow applicable government policies
If there is a conflict between this policy and an applicable government policy (e.g., Medicare LCD/NCD or state Medicaid), the government policy governs determinations; failure to follow the controlling government policy may risk denial.
- Check applicable Medicare/Medicaid local and national coverage policies for members covered by those programs.
Combination testing requirement for G0476
G0476 requires that high‑risk HPV nucleic acid testing be performed in addition to a Pap test; failing to perform the required combination testing could affect billing and lead to denial.
- When using G0476, ensure concurrent Pap test performance and documentation per the code description.
Background and Scope
Cervical cancer screening is intended to detect precancerous lesions and invasive cancer using Pap cytology, high‑risk HPV (hr‑HPV) testing, and colposcopy when indicated. These modalities are the basis for the coverage criteria, triage (including reflex cytology or genotyping), and post‑treatment surveillance strategies described in the policy.
Definitions and Key Terms
Policy Revision History
Original documentation published and governance approved.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.